I really don't want to be a doctor

Chapter 451 Pfizer's Change

This night, the European and American tumor fields were ecstatic.

In China, however, the Shenzhou laboratory was dead silent.

But apart from the Shenzhou laboratory, other domestic laboratories in China were not affected at all, because they hadn't paid attention to this matter at all.

In other words, even if other domestic laboratories want to develop immune checkpoint inhibitors, they still have more than enough energy.

The next day, Shenzhou Laboratory was on holiday.

This is the first time that Shenzhou Laboratory has given all experimenters a holiday since it developed the "Immune Checkpoint Inhibitor" and started the scientific research competition.

Everyone thinks that Shenzhou Laboratory is slowly abandoning the "immune checkpoint inhibitor" project. Even among the members of the project team, many people hold the same point of view.

However, Jing Xiaoran and Zhu Xianqing gave everyone a two-day holiday regardless of other people's opinions.

In these two days, Jing Xiaoran just stayed at home to rest.

Occasionally watch TV series, play games, chat with parents, Xiaoxiao, and Weng Huijin, and let my mind go, not thinking about experimental research and development.

During this period of time, everyone in the Shenzhou Laboratory has spent a lot of time and energy on the "Immune Checkpoint Inhibitor" project.

The combination of work and rest is more conducive to the subsequent research and development work.

In fact, Jing Xiaoran's mood did not relax, on the contrary, he became even more nervous!

This failure sounded the alarm for him.

Even if he has relevant information about future research and development in his mind, as long as he is not careful, he will be defeated.

This failure can only happen once!
The two-day vacation is over, and everyone returns to the Shenzhou Laboratory.

Jing Xiaoran first gathered the "monoclonal antibody" project team together, appointed two main project leaders, and distributed the preliminary materials he had compiled to all project team members.

"Mr. Jing, aren't you going to participate in the experiment of this project now?" Cheng Bo, one of the project leaders, asked suspiciously.

"I won't join for the time being." Jing Xiaoran shook his head and said, "But if you find any problems in the research and development, you can come to me. I am still finishing the immune checkpoint inhibitor project."

"Oh." Cheng Bo understood, he felt that Jing Xiaoran was going to deal with the aftermath of the "Immune Checkpoint Inhibitor" project team, so he didn't say much.

After the members of the "monoclonal antibody" project team left, Jing Xiaoran gathered the remaining members of the "immune checkpoint inhibitor" project team together.

in the conference room.

Including Jing Xiaoran and Zhu Xianqing, there are only 18 remaining members of "Immune Checkpoint Inhibitors"!
For a large experimental study, the number of people is really too small.

For labs with prices like AstraZeneca and Pfizer, there are often 50 or [-] people for each large-scale experimental research!

Fortunately, 99% of the experiments on immune checkpoint inhibitors have been completed, and there are not many resources needed in the future.

"Do you have a lot of doubts, or are you angry?"

Jing Xiaoran's calm voice sounded in the laboratory.

Everyone was silent.

It's embarrassing for anyone to encounter this kind of thing.

"but!"

The score of Jing Xiaoran's voice suddenly increased by an octave.

"What I want to tell you is that Shenzhou Laboratories will not give up the immune checkpoint inhibitor project. On the contrary, in the next period of time, the immune checkpoint inhibitor project team will be more important! I hope everyone can come up with more I have more motivation before, and I will face all the challenges in the future!"

As soon as the words fell, except for Zhu Xianqing, everyone else looked at Jing Xiaoran in surprise.

More emphasis on immune checkpoint inhibitors?
If it is really important, why split the project team!
Jing Xiaoran's words sounded again, seeming to respond to everyone's doubts in their hearts, "There are not many remaining experiments. If the experimenters are more complicated, the research and development efficiency will not be greatly improved. Moreover, Mr. Zhu Xianqing and I have re-planned. After completing all the R&D plans, what is needed now is for everyone to work together and make the final sprint!"

Below the conference room, after listening to Jing Xiaoran's words, Ah Wei finally understood what Hong Sheng said to him two days ago.

As for the rest of the lab, the expressions on their faces changed from surprise to joy.

The laboratory has not given up on immune checkpoint inhibitors, which means there is still hope!

At this time, Zhu Xianqing said: "We have just completed the first phase of the scientific research competition with AstraZeneca, and two-thirds of the [-]-meter marathon has passed. The next three phases of clinical trials are the most important!"

Jing Xiaoran then explained all the experimental plans to everyone in detail.

This time, the Shenzhou Laboratory did not pursue speed, but instead tried to make the preliminary experiments as perfect as possible, and then entered the third phase of clinical trials!

The spark in the hearts of everyone in the "Immune Checkpoint Inhibitors" project team has been slowly ignited!
In this way, the research and development of Shenzhou Laboratory is divided into three project groups, immune checkpoint inhibitors, myocardial mesenchymal stem cells and monoclonal antibodies.

……

United States, Pfizer headquarters.

Hamer was sitting in his office frowning.

AstraZeneca's announcement this time that "immune checkpoint inhibitors" have entered phase III clinical trials is a big blow to Pfizer!
Not only will it affect the ecology of the field of tumor drugs, but it will also interfere with Pfizer's future strategic work.

If Shenzhou Laboratory is the first to enter Phase III clinical trials, Pfizer would be more likely to accept it.

For one thing, the background of Shenzhou Laboratory is not deep enough to have an impact on Pfizer.Secondly, the Shenzhou laboratory is located in Asia, which will not affect Pfizer for the time being.

Therefore, Hammer is more willing to see that Shenzhou Laboratories can take the lead in developing immune checkpoint inhibitors, and perhaps he can also obtain the agency rights of the drug in the United States from Jing Xiaoran.

However, the current situation has changed. AstraZeneca has taken the lead, and there has been no movement from the Shenzhou laboratory.

Hamer, as the management of Pfizer who is more optimistic about the Chinese market, is under a lot of pressure at this moment!
In the capitalist world, you can be promoted because of the rise of the Chinese market, or you can be excluded because of the Chinese market.

"Then give up."

Hammer shook his head, picked up a pen, and crossed out the names of Jing Xiaoran and Shenzhou Laboratory in a document.

From now on, Pfizer's layout in the oncology field is biased towards India and European and American markets.

As for Huaxia, it was placed in the last position.

In fact, Europe and the United States have always looked down upon China's domestic drug research and development circle.

If it hadn't been for Jing Xiaoran who developed a new type of oral anticoagulant drug, Pfizer would not have valued China's R&D market so much.

……

Jing Xiaoran himself could feel the change in Pfizer's attitude towards Shenzhou Lab.

Hammer used to call every two or three days to ask questions, but now it's been half a month, and Hammer hasn't contacted him yet.

(End of this chapter)